PCSK9 and osteoporosis: Following the meta-analysis, it was observed that PCSK9 inhibitors had an increased risk of osteoporosis (Common effects model: OR: 1.00, 95% CI 1.00-1.01 P < 0.05 ) (Fig. 3 ), whereas the impact of HMGCR inhibitors on osteoporosis was not significant (Random effects model: OR: 0.99, 95% CI 0.99-1.00 P > 0.05) (Fig. 4).